The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2246-2257

  Deng, Shiwei ^a   Yan, Tiandong ^a   Nikolova, Teodora ^a   Fuhrmann, Dominik ^a   Nemecek, Andrea ^a   Gödtel Armbrust, Ute ^a   Kaina, Bernd ^a   Wojnowski, Leszek ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HISTONE H2AX; PROTEIN P53; RAZOXANE; ATF3 PROTEIN, HUMAN; ATM PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; GYRASE INHIBITOR; H2AFX PROTEIN, HUMAN; HISTONE; SIGNAL PEPTIDE; TP53 PROTEIN, HUMAN; TP53BP1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR SUPPRESSOR P53 BINDING PROTEIN 1;

ACTIVATING TRANSCRIPTION FACTOR 3 GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE RESPONSE; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEIC ACID STRUCTURE, METABOLISM AND FUNCTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; FIBROSARCOMA; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANTIGENS, NEOPLASM; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; DEXRAZOXANE; DNA BREAKS, DOUBLE-STRANDED; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSARCOMA; HISTONES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOPOISOMERASE II INHIBITORS; TRANSFECTION; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926659890     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13046     Document Type: Article

References (49)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol, 170: 1797-1867
2. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98: 13681-13686.
3. Berdelle N, Nikolova T, Quiros S, Efferth T, Kaina B, (2011). Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther 10: 2224-2233.
4. Bonnefoi HR, (2011). Anthracyclines, HER2, and TOP2A: the verdict. Lancet Oncol 12: 1084-1085.
5. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. (2008). Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 105: 9053-9058.
6. Carpenter AJ, Porter AC, (2004). Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell 15: 5700-5711.
7. Chen BP, Liang G, Whelan J, Hai T, (1994). ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem 269: 15819-15826.
8. Creighton AM, Hellmann K, Whitecross S, (1969). Antitumour activity in a series of bisdiketopiperazines. Nature 222: 384-385.
9. van Dalen EC, Caron HN, Dickinson HO, Kremer LC, (2011a). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (6): CD003917.
10. van Dalen EC, van den Berg H, Raphael MF, Caron HN, Kremer LC, (2011b). Should anthracyclines and dexrazoxane be used for children with cancer? Lancet Oncol 12: 12-13.
11. Eich M, Roos WP, Nikolova T, Kaina B, (2013). Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. Mol Cancer Ther 12: 2529-2540.
12. Eyers PA, van den Ijssel P, Quinlan RA, Goedert M, Cohen P, (1999). Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett 451: 191-196.
13. FitzGerald JE, Grenon M, Lowndes NF, (2009). 53BP1: function and mechanisms of focal recruitment. Biochem Soc Trans 37: 897-904.
14. Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, et al. (2010). Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer 10: 668.
15. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ, (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5: 1-28.
16. Hasinoff BB, Abram ME, Barnabe N, Khelifa T, Allan WP, Yalowich JC, (2001). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol 59: 453-461.
17. Hayakawa J, Depatie C, Ohmichi M, Mercola D, (2003). The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem 278: 20582-20592.
18. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159.
19. van Hille B, Hill BT, (1998). Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemother Pharmacol 42: 345-356.
20. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, et al. (1992). Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84: 1725-1730.
21. Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, et al. (2005). Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 11: 6722-6729.
22. Huang KC, Gao H, Yamasaki EF, Grabowski DR, Liu S, Shen LL, et al. (2001). Topoisomerase II poisoning by ICRF-193. J Biol Chem 276: 44488-44494.
23. Huang X, Li X, Guo B, (2008). KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 283: 29795-29801.
24. Janz M, Hummel M, Truss M, Wollert-Wulf B, Mathas S, Johrens K, et al. (2006). Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 107: 2536-2539.
25. Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, et al. (2000). A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines. J Biol Chem 275: 2137-2146.
26. Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M, et al. (2008). Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68: 8333-8341.
27. Kinner A, Wu W, Staudt C, Iliakis G, (2008). Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-5694.
28. Kool J, Hamdi M, Cornelissen-Steijger P, van der Eb AJ, Terleth C, van Dam H, (2003). Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2. Oncogene 22: 4235-4242.
29. Larsen AK, Escargueil AE, Skladanowski A, (2003). Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99: 167-181.
30. Lee SH, Bahn JH, Whitlock NC, Baek SJ, (2010). Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 29: 5182-5192.
31. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. (2007). Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67: 8839-8846.
32. Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, et al. (2009). Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 255: 72-79.
33. Nikolova T, Dvorak M, Jung F, Adam I, Kramer E, Gerhold-Ay A, et al. (2014). The γH2AX assay for genotoxic and nongenotoxic agents: comparison of H2AX phosphorylation with cell death response. Toxicol Sci 140: 103-117.
34. Nitiss JL, (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338-350.
35. Nobori K, Ito H, Tamamori-Adachi M, Adachi S, Ono Y, Kawauchi J, et al. (2002). ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 34: 1387-1397.
36. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
37. Sahu RP, Batra S, Srivastava SK, (2009). Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 100: 1425-1433.
38. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, et al. (1998). Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58: 1460-1468.
39. Snyder RD, (2003). Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons. Drug Chem Toxicol 26: 15-22.
40. Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, et al. (1999). Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 17: 880-886.
41. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA, (1997a). Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15: 1333-1340.
42. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. (1997b). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318-1332.
43. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. (2007). Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25: 493-500.
44. Turchi L, Aberdam E, Mazure N, Pouyssegur J, Deckert M, Kitajima S, et al. (2008). Hif-2alpha mediates UV-induced apoptosis through a novel ATF3-dependent death pathway. Cell Death Differ 15: 1472-1480.
45. Turchi L, Fareh M, Aberdam E, Kitajima S, Simpson F, Wicking C, et al. (2009). ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. Cell Death Differ 16: 728-737.
46. Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, et al. (1999). Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res 59: 3442-3450.
47. Wu X, Nguyen BC, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. (2010). Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 465: 368-372.
48. Yamada N, Noguchi S, Mori T, Naoe T, Maruo K, Akao Y, (2013). Tumor-suppressive microRNA-145 targets catenin delta-1 to regulate Wnt/beta-catenin signaling in human colon cancer cells. Cancer Lett 335: 332-342.
49. Yan T, Deng S, Metzger A, Godtel-Armbrust U, Porter AC, Wojnowski L, (2009). Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther 8: 1075-1085.